Can Helus Pharma (HELP) Stock Reach $40?

Helus Pharma Inc. (Nasdaq: HELP) — formerly Cybin Inc., rebranded in late 2025 and moved to the Nasdaq in January 2026 — is a clinical-stage biopharmaceutical company developing novel serotonergic agonists (NSAs), synthetic molecules engineered to promote neuroplasticity and treat depression and anxiety. After a powerful run, the stock trades near $11, while the average analyst price target sits near $40, roughly four times the current level. That gap frames a simple question: Can HELP reach $40?

Key Takeaways

• The central target of $40 is the arithmetic mean of roughly 11 current analyst price targets, which span a wide range from about $15 to $70.
• With the latest verified close near $11.03, reaching $40 would require roughly 263% upside — a very large move, even by clinical-stage biotech standards.
• Every covering analyst rates the stock Buy or Overweight, a rare degree of unanimity, yet target dispersion reflects genuine uncertainty about a binary clinical catalyst.
• The dominant catalyst is topline Phase 3 data for HLP003 in major depressive disorder (MDD), expected around mid-to-late November 2026.
• The biggest risks are the pre-revenue business model, possible trial disappointment, share dilution from capital raises, and regulatory hurdles.

Analyst Price Targets and Consensus View

Across roughly 11 covering analysts tracked by S&P Global, the average 12-month HELP price target is near $40, with a "Strong Buy" consensus and a low-to-high range of approximately $15 to $70. The figure used here is the arithmetic mean of those verified targets, rounded to a clean level — not the highest or lowest estimate.

The spread is unusually wide, which reflects disagreement about the probability of clinical success and the company's eventual valuation. On the optimistic end, H.C. Wainwright carries a $70 target (reiterated October 8, 2026, after trimming from $95), while TD Cowen raised its target to $62 from $8 in August 2026. Bloom Burton holds a $47 target, and Canaccord Genuity reiterated $42 in late September. On the more cautious side, Barclays initiated coverage at $35 in September 2026, Jefferies maintains $22, Wells Fargo holds a $16 target after initiating in July, and Alliance Global Partners lowered its target to $15 in July 2026.

Analysts generally anchor their numbers to a probability-weighted view of HLP003 approval, peer comparisons such as COMPASS Pathways (CMPS), and the belief that the stock trades below the value of its late-stage pipeline. TD Cowen cited improved visibility into Phase 3 timing and a newly appointed chief executive, while Wells Fargo pointed to COMP360 data as a readthrough supporting HLP003.

Current Market Position and Path Toward the Target

HELP closed near $11.03 on October 12, 2026, giving the company a market capitalization around $800 million. The stock sits within a 52-week range of $3.76 to $15.15, having rallied more than 80% over the past year. To reach $40, the share price would need to climb roughly 263%, a move best described as very large.

The realistic path runs through a single event: positive Phase 3 results for HLP003, a deuterated psilocybin analog being studied as an adjunctive treatment for MDD. The pivotal APPROACH trial enrolled 223 adults whose symptoms persist despite existing antidepressants, with topline data expected in the second or third week of November 2026. Success would likely trigger a sharp repricing toward analyst targets; a miss could unwind much of the recent gain.

What Could Support a Move Toward the Target

• Late-stage catalyst: HLP003 has FDA Breakthrough Therapy Designation, and a positive Phase 3 readout could materially de-risk the pipeline.
• Sector momentum: Encouraging data from psychedelic neuropsychiatry peers has lifted sentiment across the category.
• Leadership and visibility: A new, experienced chief executive and clearer trial timelines have improved confidence, as reflected in several target increases.
• Cash position: The company reported roughly $200 million in cash late in 2025, funding operations into 2027 and reducing near-term financing risk.

What Could Prevent the Target From Being Reached

• Binary trial risk: HLP003 generates no meaningful revenue today, and a failed or ambiguous Phase 3 result would likely compress the valuation sharply.
• Dilution: Follow-on offerings have repeatedly diluted shareholders, and H.C. Wainwright cited dilution and delayed launch timing when cutting its target from $95 to $70.
• Regulatory uncertainty: Approval and commercialization of psychedelic-derived therapies remain subject to FDA and payer decisions that are not guaranteed.
• Valuation: On a price-to-book basis the stock screens expensive versus pharmaceutical peers, meaning expectations are already elevated.

Technical Levels and Market Structure

HELP currently trades below its 52-week high of $15.15, which now acts as a meaningful resistance level. A sustained move above $15 would be the first technical hurdle on any path toward $40, while the 52-week low of $3.76 marks the lower bound of the recent trading range. The stock's long-term trend has improved sharply, but the gap between the current price and analyst targets means any advance would need to clear multiple prior highs and psychological price levels before approaching the central target.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual timelines vary. The most important near-term event is the HLP003 Phase 3 topline readout expected around mid-to-late November 2026, which will likely dominate the stock's direction. Investors should also watch upcoming quarterly results, any analyst target revisions following the data, regulatory commentary on psychedelic therapies, and signs of additional financing or insider activity. None of these items offers a definitive forecast, but together they will determine whether the $40 objective remains in play.

AI Daily Buy/Sell Signals

For traders tracking fast-moving clinical-stage names like HELP, Tickeron's AI Daily Buy/Sell Signals offer a way to monitor shifting conditions without watching every tick. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market behavior, technical patterns, and AI-driven analysis. Traders can use these signals to uncover opportunities, track existing positions, and identify changing trends more efficiently as sentiment shifts around catalysts. Explore the AI Daily Buy/Sell Signals to see how the tool fits your workflow.

Final Assessment

The $40 central target for HELP represents the arithmetic mean of a wide analyst range — roughly $15 to $70 — and implies a very large move of about 263% from the latest price near $11.03. Support rests on a pivotal Phase 3 catalyst, Breakthrough Therapy Designation, favorable sector sentiment, and new leadership, while the principal obstacles are binary clinical risk, shareholder dilution, and regulatory uncertainty. The wide spread between bullish and cautious targets reflects genuine disagreement rather than confidence. The November HLP003 readout, not the headline target itself, is the factor most likely to determine whether the stock can approach $40.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations